Limitations of sacubitril/valsartan in the management of heart failure

American Journal of Therapeutics

Volumn 24, Issue 2, 2017, Pages e234-e239

  Yandrapalli, Srikanth ^a   Aronow, Wilbert S ^a   Mondal, Pratik ^a   Chabbott, David R ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Entresto; Heart failure with reduced ejection fraction; LCZ696; Neprilysin inhibitor; Sacubitril valsartan

Indexed keywords

SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; MEMBRANE METALLOENDOPEPTIDASE; TETRAZOLE DERIVATIVE;

ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DRUG INFORMATION; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; PHARMACEUTICAL CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; AFRICAN AMERICAN; ALZHEIMER DISEASE; ANTAGONISTS AND INHIBITORS; CAUCASIAN; CHEMICALLY INDUCED; HYPOTENSION; PATIENT DROPOUT; RISK FACTOR;

AFRICAN AMERICANS; ALZHEIMER DISEASE; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEART FAILURE; HUMANS; HYPOTENSION; NEPRILYSIN; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TETRAZOLES;

EID: 84984694222     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000473     Document Type: Article

References (33)

1. Davis RC, Hobbs FD, Lip GY. ABC of heart failure: history and epidemiology. BMJ. 2000;320:39-42
2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American heart association Task Force on practice guidelines. Circulation. 2013;128:1810-1852
3. Braunwald E. The war against heart failure: the Lancet lecture. Lancet. 2015;385:812-824
4. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38-e360
5. Bevan EG, Connell JM, Doyle J, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992;10:607-613
6. Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. Lancet. 1998;351:1657-1658
7. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-111
8. McMurray JJ, Packer M, Desai AS, et al. Angiotensinneprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004
9. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401-414
10. Hegde LG, Yu C, Madhavi C, et al. Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension. BMC Pharmacol. 2011;11:P33
11. Ruilope LM, Dukat A, Bohm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255-1266
12. Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63:698-705
13. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387-1395
14. McMurray J, Packer M, Desai AS, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2015;36:434-439
15. Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54-61
16. Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36:1990-1997
17. Kristensen SL, Preiss D, Jhund PS, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail. 2016;9:e002560
18. Solomon S, Packer M, Zile M, et al. The angiotensin receptor neprilysin inhibitor LCZ696 is effective across the spectrum of ejection fraction in heart failure with reduced ejection fraction. J Card Fail. 2015;21:S45-S46
19. Simpson J, Jhund PS, Silva Cardoso J, et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015;66:2059-2071
20. Böhm M, Refsgaard J, Ramires FJA. Effect of angiotensin receptor neprilysin inhibitor LCZ696 compared with enalapril according to systolic blood pressure in PARADIGM-HF. Eur J Heart Fail. 2015;17(suppl 1):393
21. Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36:2576-2584
22. Moe GW, Ezekowitz JA, O'Meara E, et al. The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications. Can J Cardiol. 2015; 31:3-16
23. Judge P, Haynes R, Landray MJ, et al. Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transpl. 2015; 30:738-743
24. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302
25. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of Utility in reducing events (OVERTURE). Circulation. 2002;106:920-926
26. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112:2426-2435
27. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensinconverting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999; 100:2312-2318
28. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675
29. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906. [Erratum, N Engl J Med. 2004;350:203.]
30. Boshuizen HC, Izaks GJ, van Buuren S, et al. Blood pressure and mortality in elderly people aged 85 and older: community based study. BMJ. 1998;316:1780-1784
31. Ni H, Xu J. Recent Trends in Heart Failure-Related Mortality: United States, 2000-2014. NCHS Data Brief, No 231. Hyattsville, MD: National Center for Health Statistics; 2015
32. Nalivaeva NN, Belyaev ND, Kerridge C, et al. Amyloidclearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease. Front Aging Neurosci. 2014;6:235
33. Vodovar N, Paquet C, Mebazaa A, et al. Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split Eur Heart J. 2015;36:902-905.